Cargando…
A polymorphism in ABCC4 is related to efficacy of 5-FU/capecitabine-based chemotherapy in colorectal cancer patients
To investigate the association of microRNA (miRNA) binding-site polymorphisms in the drug transporter genes with the efficacy of 5-Fluorouracil (5-FU)/capecitabine-based chemotherapy in colorectal cancer (CRC), 6 polymorphisms were determined in 432 CRC patients by using DNA sequencing method. The i...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5539293/ https://www.ncbi.nlm.nih.gov/pubmed/28765596 http://dx.doi.org/10.1038/s41598-017-07491-3 |
_version_ | 1783254462180098048 |
---|---|
author | Chen, Qi Meng, Fanyi Wang, Lei Mao, Yong Zhou, Huan Hua, Dong Zhang, Hongjian Wang, Weipeng |
author_facet | Chen, Qi Meng, Fanyi Wang, Lei Mao, Yong Zhou, Huan Hua, Dong Zhang, Hongjian Wang, Weipeng |
author_sort | Chen, Qi |
collection | PubMed |
description | To investigate the association of microRNA (miRNA) binding-site polymorphisms in the drug transporter genes with the efficacy of 5-Fluorouracil (5-FU)/capecitabine-based chemotherapy in colorectal cancer (CRC), 6 polymorphisms were determined in 432 CRC patients by using DNA sequencing method. The impacts of the polymorphisms on the miRNA-mediated regulation of gene expression were evaluated by using the methods including quantitative real-time PCR, western blotting, and luciferase reporter assays. The effects of miRNA on the intracellular concentration and cytotoxicity of 5-FU in CRC cells were measured by high performance liquid chromatography conjected tandem mass spectrometry (HPLC-MS/MS) and MTT methods, respectively. Statistical analysis showed that a polymorphism rs3742106 in the 3′-UTR of ATP-binding cassette subfamily C member 4 (ABCC4) gene was significantly associated with the efficacy of 5-FU/capecitabine-based chemotherapy in CRC. The patients with T/T genotype had significantly higher response rate than those with G/G and G/T genotypes. The expression of ABCC4 was inhibited by miR-3190-5p through binding to the 3′-UTR of the ABCC4 gene. This regulatory role of miR-3190-5p was disrupted by rs3742106. Furthermore, we found that the intracellular concentration of 5-FU was elevated by miR-3190-5p, and consequently the sensitivity of CRC cells to 5-FU was also enhanced. Rs3742106 might be regarded as a genetic biomarker for individualized use of 5-FU and capecitabine in CRC. |
format | Online Article Text |
id | pubmed-5539293 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-55392932017-08-07 A polymorphism in ABCC4 is related to efficacy of 5-FU/capecitabine-based chemotherapy in colorectal cancer patients Chen, Qi Meng, Fanyi Wang, Lei Mao, Yong Zhou, Huan Hua, Dong Zhang, Hongjian Wang, Weipeng Sci Rep Article To investigate the association of microRNA (miRNA) binding-site polymorphisms in the drug transporter genes with the efficacy of 5-Fluorouracil (5-FU)/capecitabine-based chemotherapy in colorectal cancer (CRC), 6 polymorphisms were determined in 432 CRC patients by using DNA sequencing method. The impacts of the polymorphisms on the miRNA-mediated regulation of gene expression were evaluated by using the methods including quantitative real-time PCR, western blotting, and luciferase reporter assays. The effects of miRNA on the intracellular concentration and cytotoxicity of 5-FU in CRC cells were measured by high performance liquid chromatography conjected tandem mass spectrometry (HPLC-MS/MS) and MTT methods, respectively. Statistical analysis showed that a polymorphism rs3742106 in the 3′-UTR of ATP-binding cassette subfamily C member 4 (ABCC4) gene was significantly associated with the efficacy of 5-FU/capecitabine-based chemotherapy in CRC. The patients with T/T genotype had significantly higher response rate than those with G/G and G/T genotypes. The expression of ABCC4 was inhibited by miR-3190-5p through binding to the 3′-UTR of the ABCC4 gene. This regulatory role of miR-3190-5p was disrupted by rs3742106. Furthermore, we found that the intracellular concentration of 5-FU was elevated by miR-3190-5p, and consequently the sensitivity of CRC cells to 5-FU was also enhanced. Rs3742106 might be regarded as a genetic biomarker for individualized use of 5-FU and capecitabine in CRC. Nature Publishing Group UK 2017-08-01 /pmc/articles/PMC5539293/ /pubmed/28765596 http://dx.doi.org/10.1038/s41598-017-07491-3 Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Chen, Qi Meng, Fanyi Wang, Lei Mao, Yong Zhou, Huan Hua, Dong Zhang, Hongjian Wang, Weipeng A polymorphism in ABCC4 is related to efficacy of 5-FU/capecitabine-based chemotherapy in colorectal cancer patients |
title | A polymorphism in ABCC4 is related to efficacy of 5-FU/capecitabine-based chemotherapy in colorectal cancer patients |
title_full | A polymorphism in ABCC4 is related to efficacy of 5-FU/capecitabine-based chemotherapy in colorectal cancer patients |
title_fullStr | A polymorphism in ABCC4 is related to efficacy of 5-FU/capecitabine-based chemotherapy in colorectal cancer patients |
title_full_unstemmed | A polymorphism in ABCC4 is related to efficacy of 5-FU/capecitabine-based chemotherapy in colorectal cancer patients |
title_short | A polymorphism in ABCC4 is related to efficacy of 5-FU/capecitabine-based chemotherapy in colorectal cancer patients |
title_sort | polymorphism in abcc4 is related to efficacy of 5-fu/capecitabine-based chemotherapy in colorectal cancer patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5539293/ https://www.ncbi.nlm.nih.gov/pubmed/28765596 http://dx.doi.org/10.1038/s41598-017-07491-3 |
work_keys_str_mv | AT chenqi apolymorphisminabcc4isrelatedtoefficacyof5fucapecitabinebasedchemotherapyincolorectalcancerpatients AT mengfanyi apolymorphisminabcc4isrelatedtoefficacyof5fucapecitabinebasedchemotherapyincolorectalcancerpatients AT wanglei apolymorphisminabcc4isrelatedtoefficacyof5fucapecitabinebasedchemotherapyincolorectalcancerpatients AT maoyong apolymorphisminabcc4isrelatedtoefficacyof5fucapecitabinebasedchemotherapyincolorectalcancerpatients AT zhouhuan apolymorphisminabcc4isrelatedtoefficacyof5fucapecitabinebasedchemotherapyincolorectalcancerpatients AT huadong apolymorphisminabcc4isrelatedtoefficacyof5fucapecitabinebasedchemotherapyincolorectalcancerpatients AT zhanghongjian apolymorphisminabcc4isrelatedtoefficacyof5fucapecitabinebasedchemotherapyincolorectalcancerpatients AT wangweipeng apolymorphisminabcc4isrelatedtoefficacyof5fucapecitabinebasedchemotherapyincolorectalcancerpatients AT chenqi polymorphisminabcc4isrelatedtoefficacyof5fucapecitabinebasedchemotherapyincolorectalcancerpatients AT mengfanyi polymorphisminabcc4isrelatedtoefficacyof5fucapecitabinebasedchemotherapyincolorectalcancerpatients AT wanglei polymorphisminabcc4isrelatedtoefficacyof5fucapecitabinebasedchemotherapyincolorectalcancerpatients AT maoyong polymorphisminabcc4isrelatedtoefficacyof5fucapecitabinebasedchemotherapyincolorectalcancerpatients AT zhouhuan polymorphisminabcc4isrelatedtoefficacyof5fucapecitabinebasedchemotherapyincolorectalcancerpatients AT huadong polymorphisminabcc4isrelatedtoefficacyof5fucapecitabinebasedchemotherapyincolorectalcancerpatients AT zhanghongjian polymorphisminabcc4isrelatedtoefficacyof5fucapecitabinebasedchemotherapyincolorectalcancerpatients AT wangweipeng polymorphisminabcc4isrelatedtoefficacyof5fucapecitabinebasedchemotherapyincolorectalcancerpatients |